Dolutegravir product-specific bioequivalence guidance

Current effective version

PDF iconAdopted guideline

Reference numberEMA/CHMP/356874/2017
Effective from01/08/2018
KeywordsBioequivalence, generics, dolutegravir
DescriptionThis document provides product-specific guidance on the demonstration of the bioequivalence of olutegravir.
  • BCS Classification: Biopharmaceutics Classification System
  • AUC0-t: area under the plasma concentration curve from administration to last observed concentration at time t
  • Cmax: maximum plasma concentration

Document history

First version

Current version

PDF iconAdopted guideline

PDF iconDraft guideline

In operation: 01/08/2018-present

Published: 28/07/2017

Related content

How useful was this page?

Add your rating